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Abstract A new method for the fast synthesis of diverse 4-aryl-6-
cycloamino-1,3,5-triazin-2-amines was developed.  The synthesis is 
performed under microwave irradiation in a one-pot manner from 
cyanoguanidine, aromatic aldehydes, and cyclic amines.  Their three-
component reaction in the presence of hydrochloric acid produced 
dihydrotriazines, which were then converted (without isolation) to the 
targeted compounds via aromatic dehydrogenation in the presence of 
alkali.  The reaction tolerated various aromatic aldehydes (including 
heterocyclic) and cyclic amines.  Crystal structures of two representative 4-
aryl-6-morpholino-1,3,5-triazin-2-amines were established by X-ray 
crystallography.  The results of preliminary biological screening identified 
potent antileukemic activity for 6-(3,4-dihydroisoquinolin-2(1H)-yl)-4-
phenyl-1,3,5-triazin-2-amine.   
Key words Triazines, Multicomponent reactions, Microwave-assisted 
synthesis, Dehydrogenative aromatization; Antiproliferative activity 
 
1,3,5-Triazines have been one of the most widely used classes 
of herbicides for the last half-century.1  In veterinary medicine, 
triazines (including 1,3,5-triazines toltrazuril and ponazuril) 
form a well-established class of antiprotozoal drugs.2  In the 
contemporary design of new bioactive compounds with 
potential therapeutic applications, the 1,3,5-triazine ring has 
also proven to be a privileged scaffold.3-5  Despite a wide range 
of biological activities reported for 1,3,5-triazines, 
achievements in the development of anticancer agents based 
on this skeleton were particularly important.6,7  Recently 
approved anticancer drugs include 1,3,5-triazines Enasidenib8,9 
and Gedatolisib10,11 (Fig. 1).  The 1,3,5-triazine ring of these 
drugs is decorated in positions 2, 4, and 6 with two substituted 
amino groups and a (het)aryl moiety.  The inhibitors of 
Bruton’s tyrosine kinase12 and lysophosphatidic acid 
acyltransferase β13-15 and recently reported16 highly potent and 
selective agents targeting triple-negative breast cancer share a 
similar 4-(het)aryl-6-arylamino-1,3,5-triazin-2-amine scaffold.  
Structurally related compounds with 6-aralkylamino 
substitution demonstrated potent inhibition of tryptophan 
hydroxylase17 and an effective positive allosteric modulation of 
G protein-coupled receptor 68 (GPR68).18,19  The inhibitors of 
phosphoinositide 3-kinase20 and ligands for H4 histamine 
receptors21,22 were found among 4-aryl-6-cycloamino-1,3,5-
triazin-2-amines, while similar 4-aralkyl-6-cycloamino-1,3,5-
triazin-2-amines selectively bound to 5-HT6 serotonin 
receptors.23   
The pharmacological investigation of 4-aryl-6-cycloamino-
1,3,5-triazin-2-amines (1) possessing different substitution 
patterns would open opportunities for the identification of new 
potent bioactive agents.  However, existing methods for the 
preparation of these compounds are limited and do not allow 
fast synthesis of sufficiently diverse molecules.  
One of the methods for the synthesis of 4-aryl-6-cycloamino-
1,3,5-triazin-2-amines (1) utilizes cyanuric chloride, which is 
involved in a sequential nucleophilic substitution with cyclic 
amines (e.g. morpholine) and then ammonia; the Suzuki cross-
coupling of the resulting intermediate with arylboronic acids 
concludes this approach (Scheme 1, Route 1).20  
Another general approach for the synthesis of 1 relies on the 
reactions of biguanides, derived from cyanoguanidine and 
cyclic amines, with different reagents (Route 2).  The reaction 
of biguanides with benzoin is highly sensitive to pH and 
structure substrates24 making the scope of this method for the 
preparation of 4-aryl-6-cycloamino-1,3,5-triazin-2-amines 
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limited.  The condensation of biguanides with carboxylic acid 
derivatives, e.g. esters in the presence of strong bases, is the 
most common method for the synthesis of 1.25  Recently, N,N-
dimethyl-substituted amides were employed in the 
imidazolium-catalyzed reaction with biguanides resulting in 
the triazine ring closure.26  However, this reaction was more 
applicable to DMF as a one-carbon inserting synthon and only 
one 4-aryl derivative was prepared by this method.26  Benzyl 
alcohols were reported to react with biguanides under the 
ruthenium27 or graphene oxide28 catalysis affording 4-aryl-6-
cycloamino-1,3,5-triazin-2-amines (1).  Being more general in 
scope, these methods suffer from relatively long reaction time 
(heating for up to 30 h in the second step).  
Recently, we developed a new method for the synthesis of 6,N2-
diaryl-1,3,5-triazin-2,4-diamines (3) via one-pot three-
component condensation, followed by the Dimroth 
rearrangement and dehydrogenative aromatization of the 
dihydrotriazine intermediate 2 (Scheme 2).29  This method was 
efficiently applied to a wide range of substrates and afforded 
compounds with significant anticancer activity.30  The three-
component synthesis of dihydrotriazines 4 has not been 
reported.  Moreover, secondary amines and all aliphatic amines 
failed to afford dihydrotriazines in earlier attempts31 to involve 
them in the three-component reaction with cyanoguanidine 
and aldehydes.  Nevertheless, we decided to attempt 
performing the three-component synthesis of 4 under 
microwave irradiation also suggesting that upon heating in the 
presence of a base, these intermediate would undergo 
dehydrogenative aromatization to afford the desired triazines 
1 (Scheme 2).  Performing both of these transformations in a 
one-pot manner would make this method more practical for 
the fast synthesis of diverse 4-aryl-6-cycloamino-1,3,5-triazin-
2-amines (1).  Microwave irradiation has demonstrated a great 
utility in the multicomponent reactions32 and for the 
preparation of 1,3,5-triazines33 improving the efficiency of 
synthetic procedures.  Herein we report the development of a 
new method for the synthesis of 4-aryl-6-cycloamino-1,3,5-
triazin-2-amines (1) via the proposed approach under 
microwave irradiation.  
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Scheme 2 One-pot three-component synthesis of 6,N2-diaryl-1,3,5-triazin-
2,4-diamines (3) and proposed synthesis of 4-aryl-6-cycloamino-1,3,5-triazin-
2-amines (1). 
 
For the trial reaction and the subsequent condition 
optimization, we utilized the model reaction of cyanoguanidine 
with p-tolualdehyde and morpholine under controlled 
microwave irradiation in a Monowave 400 reactor (Anton Paar, 
Austria) (Table 1).  Replicating the reaction conditions from our 
protocol developed earlier for the synthesis of 6,N2-diaryl-1,3,5-
triazin-2,4-diamines (3),29 we were delighted to observe the 
formation of desired product 1f, which was easily isolated by 
simple filtration in 37% yield (Table 1, entry 2).  Changing the 
solvent from EtOH to MeOH or PrOH resulted in lower yields 
(entries 1 and 3).  Attempts to increase or decrease the reaction 
temperature also had a negative impact on yields of 1f (entries 4 
and 5) and further optimization was continued at 140 °C using 
EtOH as a reaction medium.  It was found that an increase in the 
duration of the first step benefited the reaction outcome 
improving the yield to 44% in 55 min (entry 6).  Further 
improvement to 48% yield was achieved extending the duration 
of the second step to 20 min (entry 7).  The longer duration of 
the second step resulted in lower yields, probably due to the 
gradual degradation of the product under the reaction 
conditions (entry 8 and 9).  The addition of another equivalent 
of p-tolualdehyde at any of the steps did not improve the 
reaction outcome (entries 10 and 11).  At the same time, the 
base appeared to play a critical role in the second step.  The 
detrimental effect to the reaction outcome was observed when 
sodium hydroxide was applied in the second step in the quantity 
equimolar to hydrochloric acid added in the first step (entry 
12).  Heating without microwave irradiation under otherwise 
similar conditions using a Monowave 50 reactor resulted in 
some decrease in the yield of 1f (entry 13).  Therefore, 
microwave conditions allowing isolation of 1f in 48% yield 
(entry 7) were used for the exploration of the reaction scope 
(more detailed optimization results are available in Supporting 
Information Table S1).  It should be also noted that unlike in the 
synthesis of N2-aryl analogs of 4,34 we were unable to isolate 
intermediate 4 after the first step.   
Table 1 Optimization of reaction conditions for the synthesis of 4-(4-
methylphenyl)-6-morpholino-1,3,5-triazin-2-amine (1f) under microwave 
irradiation.a  
 
Entry Solvent Temp, °C Reaction time, min Yield,b % 
(i) (ii) 
1 MeOH 140 20 15 33 
2 EtOH 140 20 15 37 
3 PrOH 140 20 15 9 
4 EtOH 130 20 15 28 
5 EtOH 150 20 15 31 
6 EtOH 140 55 15 44 
7 EtOH 140 55 20 48 
8 EtOH 140 55 25 46 
9 EtOH 140 55 60 41 
10c EtOH 140 55 20 33 
11d EtOH 140 55 20 26 
12e EtOH 140 55 20 6 
13f EtOH 140 55 20 33 
a The reactions were performed in a Monowave 400 microwave reactor (Anton 
Paar, Austria) using cyanoguanidine (2.5 mmol), p-tolualdehyde (2.5 mmol), 
morpholine (2.5 mmol), and conc. HCl (2.5 mmol) in 2 mL of the specified solvent 
in step (i) and addition of 1 mL of 5 N NaOH (aq.) in step (ii).  
b Isolated yield calculated on the basis of cyanoguanidine.  
c The reaction was carried out using 5 mmol of p-tolualdehyde.  
d Another 2.5 mmol of p-tolualdehyde was added to the reaction mixture in step 
(ii).  
e 0.5 mL of 5 N NaOH (aq.) [2.5 mmol] was used in step (ii).  
f The reaction was performed in a Monowave 50 reactor (Anton Paar, Austria) 
without microwave irradiation.  
 
In the exploration of the method scope, different aromatic 
aldehydes and cyclic amines were examined.  The reaction of 
cyanoguanidine and morpholine with benzaldehydes tolerated 
various substituents in the aldehyde aromatic ring (Scheme 3).  
Moreover, heteroaromatic thenaldehyde was also successfully 
involved in the reaction affording 1p in 53% yield.   
Examining the scope of cyclic amines for the reaction, we found 
that in the three-component reaction with cyanoguanidine and 
benzaldehyde, morpholine could be replaced by pyrrolidine, 
piperidines, N-methylpiperazine, or tetrahydroisoquinoline thus 
affording corresponding 6-cycloamino-4-phenyl-1,3,5-triazin-2-
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Scheme 3 Scope of aromatic aldehydes for the synthesis of 4-aryl-6-
morpholino-1,3,5-triazin-2-amines (1a-p).   
 
Scheme 4 Scope of cyclic amines for the synthesis of 4-phenyl-6-cycloamino-
1,3,5-triazin-2-amines (1q-u). 
 
The proposed mechanism for the synthesis of 1 is outlined in 
Scheme 5.  In the first step, the addition of a cyclic amine to the 
acid-activated nitrile group of cyanoguanidine is followed by the 
reaction of the formed biguanide 5 with an aldehyde resulting in 
the dihydrotriazine ring closure and formation of the 
intermediate 4.  In the presence of alkali, it converts to the N-
Mannich base 6, which undergoes dehydrogenative 
aromatization resulting in the formation of 1.  It is proposed 
that the aromatization involves initial ring-opening by the alkali, 
oxidation to the N-acylbiganide 7, recyclization to 8, and 
subsequent dehydration affording the desired product 1.  
 
Scheme 5 Proposed mechanism for the synthesis of 4-aryl-6-cycloamino-
1,3,5-triazin-2-amines (1). 
 
The NMR spectroscopic data for the prepared compounds 
support proposed structure 1.  In the 13C NMR spectra of 1, the 
three downfield signals at 164.4-169.7 ppm confirm the 
formation of an electron-deficient aromatic 1,3,5-triazine ring.  
Due to extended conjugation, the triazine and a phenyl ring 
directly attached to it are coplanar.  This results in a significant 
downfield shift of the 1H NMR spectra signals attributed to 
phenyl protons located in ortho-positions to the triazine and 
experiencing its anisotropic effect.   
The electron-deficient nature of the triazine ring results in 
significant delocalization of electrons from the adjacent amino 
groups.  The protons of the primary amino group in position 2 
are therefore deshielded and their signal in 1H NMR spectra 
appear at 6.71-7.01 ppm.  The electron delocalization of the 
cycloamino nitrogen atom is particularly visible in the NMR 
spectra of 1q, which possesses a relatively more rigid 
pyrrolidine ring.  This delocalization implies a partial double 
bond character of the C-N bond connecting the rings.  In 1H and 
13C NMR spectra of 1q, the restricted rotation around this bond 
manifests in individual signals for magnetically non-equivalent 
atoms of the opposite sides of the symmetrical pyrrolidine ring.   
The 1H NMR spectrum of 1s also confirms the substantial 
delocalization of the lone pair of the piperidine nitrogen over 
the triazine ring.  The methyl group in position 4 of the 
piperidine ring stabilizes its chair conformation with 
substituents occupying equatorial positions.  The chemical shifts 
and coupling for the signals of the remaining protons also 
confirm the chair conformation of the piperidine35 in 1s.  
Additionally, the equatorial protons at carbon atoms adjacent to 
the piperidine nitrogen occur in the plane of the triazine ring 
and due to restricted rotation become magnetically non-
equivalent.  Therefore, in the 1H NMR spectrum of 1s, these 
protons give two independent signals downfield-shifted to 4.72-
4.81 ppm (Δδ≈1.7-1.8 ppm from the signals of the same protons 
in 4-methylpiperidine36) due to the anisotropic effect of the 
triazine ring.  The axial protons at the same carbon atoms are 
affected significantly less (Δδ≈0.3 ppm).  At higher temperatures 
(35 °C), two broad signals of the equatorial α-CH coalesce into a 
single peak still suggesting slow rotation around the C-N bond 
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delocalization (Fig. 2).  Upon further heating, the signal the 
equatorial α-CH transforms into the expected doublet with 
2Jgem=-13 Hz.  Due to the 1,4-substitution of the piperidine ring 
in 1s, its chair conformation remains stable at these 
temperatures.  
 
Figure 2 Restricted rotation around the C-N bond between the triazine and 
piperidine rings in 1s: signals of the equatorial α-CH of piperidine in dynamic 
1H NMR spectra. 
 
The structural assignments were further confirmed by X-ray 
crystallography data for two representative compounds 1l and 
1n; their molecular structures are illustrated in Fig. 3.  In 1l, the 
six atoms comprising the triazine ring are planar, exhibiting a 
r.m.s. deviation = 0.0074 Å.  The pendent phenyl ring is inclined 
to the central plane [N3C3/C6 dihedral angle = 26.77(5)°] and 
the dihedral angle between the triazine ring and the best plane 
through the morpholine ring (chair conformation) of 5.89(7)° is 
indicative of approximately co-planar relationship.  The 
(benzyloxy)phenyl residue is twisted as seen in the dihedral 
angle between the rings of 79.47(4)°.  The terminal ring lies in a 
position orientated towards the bay region of the molecule 
defined by the triazine and two connected rings, and is 
orthogonal to the central plane forming a dihedral angle of 
88.80(3)°.  Within the ring, the C–N bond lengths span a 
relatively narrow range, i.e. 1.3293(14) Å for C4–N5 to 
1.3546(14) Å for C2–N3, consistent with considerable 
delocalization of π-electron density over the ring; the exocyclic 
C2–N2 bond [1.3429(14) Å] lies within this range.  
The molecular structure of 1n, Fig. 3(b), presents similar 
features to that of 1l.  The r.m.s. deviation for the six atoms 
comprising triazine ring = 0.0090 Å.  The dihedral angles 
between the central plane and the attached phenyl [11.28(5)°] 
and morpholine [5.10(5)°; chair conformation] rings indicate, to 
a first approximation, co-planar relationships.  The molecule has 
the shape of the letter, U.  Within the triazine ring, significant 
delocalization of π-electron density is indicated as the range of 
C–N bond lengths is less than for 1l, i.e. 1.3318(16) Å for C4–N3 
to 1.3529(16) Å for C2–N3, and, again, as for 1l, there is no 
pattern of alternating short and long C–N bonds within the 
triazine ring; the C2–N2 bond length is 1.3366(16) Å.  
 
Figure 3 Molecular structures of (a) 1l and (b) 1n showing atom labeling 
scheme and 70% anisotropic displacement parameters.  
 
In the molecular packing of 1l, amine-N–H…N(triazine) 
hydrogen bonding assembles centrosymmetrically-related 
molecules into dimeric aggregates through eight-membered 
{…HNCN}2 supramolecular synthons, Fig. 4(a); geometric 
parameters characterizing the key interatomic contacts are 
given in the caption of Supporting Information Fig. S1.  The 
aggregates thus formed are linked into a supramolecular tape, 
approximately along [1 3 0], by amine-N–H…O(ether) hydrogen 
bonds.  The connections between tapes to form a layer in the ab-
plane are π-stacking interactions between triazine and C41-
phenyl rings as detailed in Supporting Information Fig. S1; 
layers stack along the c-axis without directional interactions 
between them. 
A more complicated expansion of supramolecular association is 
evident in the crystal of 1n whereby each molecule is connected 
to four symmetry-related molecules by conventional hydrogen 
bonding.  Thus, the hydrogen bonds prominent in the molecular 
packing are amine-N–H…O(morpholine) and amine-N–
H…N(triazine), and lead to the formation of a two-dimensional 
array in the ac-plane, Fig. 4(b); see the caption of Supporting 
Information Fig. S2 for geometric details.  Additional 
stabilization to the layer is afforded by morpholine-C–
H…O(methoxy) and morpholine-C–H…π(phenyl) contacts.  The 
layers stack along the b-axis with the directional interactions to 
consolidate the three-dimensional packing being methyl-C–
H…O(methoxy) and π-stacking interactions between triazine and 
C41-phenyl rings; a view of the unit-cell contents is shown in 
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Figure 4 Supramolecular association sustained by conventional hydrogen 
bonds in 1l and 1n: (a) the supramolecular tape in the crystal of 1l and (b) 
supramolecular layer in the crystal of 1n (non-participating hydrogen atoms 
have been omitted for clarity).  The N‒H…O and N‒H…N hydrogen bonds are 
represented by orange and blue dashed lines, respectively. 
 
The prepared compounds were screened for antiproliferative 
activity against a Jurkat-T cell line at 10 µM.  The most potent 
compound identified in the screening was 6-(3,4-
dihydroisoquinolin-2(1H)-yl)-4-phenyl-1,3,5-triazin-2-amine 
(1u), which was further tested at several concentrations 
(Supporting Information, Fig. S3) to estimate the 50% growth 
inhibition (GI50) value.  Typical antileukemic drugs 
mercaptopurine, methotrexate, and cytarabine were used as 
positive controls.  It was found that 1u inhibited cell 
proliferation in a concentration-dependent manner 
demonstrating the GI50 value of 1.95±0.25 μM.  Being more 
potent than mercaptopurine (GI50 = 11.12 ± 4.89 μM), 1u was 
less effective than methotrexate (GI50 = 0.37 ± 0.03 μM) and 
cytarabine (GI50 = 0.29 ± 0.01 μM).  Nevertheless, these results 
indicate that the search for new antileukemic agents among 4-
aryl-6-cycloamino-1,3,5-triazin-2-amines could be fruitful.  
In conclusion, we developed a new method for the fast one-pot 
synthesis of diverse 4-aryl-6-cycloamino-1,3,5-triazin-2-amines.  
This method is based on two processes: (1) acid-catalyzed 
three-component condensation of cyanoguanidine, aromatic 
aldehydes, and cyclic amines and (2) dehydrogenative 
aromatization in the presence of a base.  Overall, the method 
was found to be rather general, with similar efficacy applicable 
to various aldehydes and cyclic amines.  The main advantage of 
the method is the potential for quick and convenient access to 
structurally diverse 4-aryl-6-cycloamino-1,3,5-triazin-2-amines 
for their biological evaluations.  Preliminary data from the 
antileukemic screening of prepared 4-aryl-6-cycloamino-1,3,5-
triazin-2-amines were promising.  Further investigations are 
under way and the results will be reported in due course.  
The experimental section has no title; please leave this line here. 
General information 
Melting points (uncorrected) were determined on a Stuart™ SMP40 
automatic melting point apparatus.  1H and 13C NMR spectra were 
recorded on a Bruker Fourier NMR spectrometer (300 MHz) using 
DMSO-d6 as a solvent and TMS as an internal reference.  Microwave-
assisted reactions were carried out in the closed vessel focused single 
mode using a Monowave 400 microwave synthesizer (Anton Paar, 
Austria) monitoring reaction temperature by the equipped IR sensor.  
The control experiment using conventional heating was performed in a 
Monowave 50 (Anton Paar, Austria) reactor.  
General procedure for the preparation of 4-aryl-6-cycloamino-
1,3,5-triazin-2-amines (1).  
To a solution of cyanoguanidine (0.21 g, 2.5 mmol), (het)arylaldehyde 
(2.5 mmol) and cyclic amine (2.5 mmol) in EtOH (2 mL) in a 10 mL 
seamless pressure vial, conc. HCl (0.21 mL, 2.5 mmol) was added. The 
reaction mixture was irradiated in the Monowave 400 (Anton Paar, 
Austria) microwave reactor operating at maximal microwave power up 
to 850 W at 140 °C for 55 min. After cooling to rt, an aq. solution of NaOH 
(5 N, 1 mL) was added to the reaction mixture and irradiation continued 
for another 20 min at 140 °C.  After cooling, the precipitated product was 
filtered, washed with water and recrystallized from an appropriate 
solvent affording desired products 1.  
6-Morpholino-4-phenyl-1,3,5-triazin-2-amine (1a).  
White solid; yield 224 mg (35%); mp 119-121 °C (EtOH), lit.37 121-123 
°C. 1H NMR (300 MHz, DMSO-d6): δ 3.63-3.67 (4H, m, CH2OCH2), 3.80 
(4H, br s, CH2NCH2), 6.94 (2H, br s, NH2), 7.43-7.55 (3H, m, H-3′, H-4′, and 
H-5′), 8.28-8.32 (2H, m, H-2′ and H-6′). 13C NMR (75 MHz, DMSO-d6): δ 
43.1 (CH2NCH2), 65.9 (CH2OCH2), 127.7 (2C), 128.1 (2C), 131.2, 136.8, 
164.9 (C-6), 167.1 (C-2), 169.6 (C-4). Anal. Calcd for C13H15N5O: C, 60.69; 
H, 5.88; N, 27.22. Found: C, 60.54; H, 5.93; N, 27.07. 
4-(3-Fluorophenyl)-6-morpholino-1,3,5-triazin-2-amine (1b).  
White solid; yield 215 mg (31%); mp 143-144 °C (EtOH). 1H NMR (300 
MHz, DMSO-d6): δ 3.63-3.68 (4H, m, CH2OCH2), 3.80 (4H, br s, CH2NCH2), 
7.03 (2H, br s, NH2), 7.37 (1H, ddt, J = 0.9, 2.7, 8.5 Hz, H-4′), 7.53 (1H, ddd, 
J = 6.0, 8.0, 8.0 Hz, H-5′), 8.01 (1H, ddd, J = 1.4, 2.7, 10.6 Hz, H-2′), 8.14 
(1H, ddd, J = 1.2, 1.2, 7.8 Hz, H-6′). 13C NMR (75 MHz, DMSO-d6): δ 43.1 
(CH2NCH2), 65.9 (CH2OCH2), 114.0 (d, J = 22.9 Hz), 118.0 (d, J = 21.1 Hz), 
123.7 (d, J = 3.0 Hz), 130.2 (d, J = 7.5 Hz), 139.6 (d, J = 7.5 Hz), 162.1 (d, J 
= 242.2 Hz), 164.8 (C-6), 167.1 (C-2), 168.5 (d, J = 3.1 Hz, C-4). Anal. 
Calcd for C13H14FN5O: C, 56.72; H, 5.13; N, 25.44. Found C, 56.55; H, 5.20; 
N, 25.32. 
4-(4-Fluorophenyl)-6-morpholino-1,3,5-triazin-2-amine (1c).  
White solid; yield 239 mg (35%); mp 186-187 °C (EtOH). 1H NMR (300 
MHz, DMSO-d6): δ 3.63-3.67 (4H, m, CH2OCH2), 3.79 (4H, br s, CH2NCH2), 
6.96 (2H, br s, NH2), 7.29 (2H, dd, J = 8.8, 8.8 Hz, H-3′ and H-5′), 8.35 (2H, 
dd, J = 5.9, 8.7 Hz, H-2′ and H-6′). 13C NMR (75 MHz, DMSO-d6): δ 43.1 
(CH2NCH2), 65.9 (CH2OCH2), 115.0 (2C, d, J = 21.6 Hz), 130.1 (2C, d, J = 
8.9 Hz), 133.3 (d, J = 2.2 Hz), 164.1 (d, J = 248.3), 164.8 (C-6), 167.1 (C-2), 
168.7 (C-4). Anal. Calcd for C13H14FN5O: C, 56.72; H, 5.13; N, 25.44. 
Found: C, 56.59 H, 5.20; N, 25.32. 
4-(4-Chlorophenyl)-6-morpholino-1,3,5-triazin-2-amine (1d).  
Yellowish solid; yield 264 mg (36%); mp 203-204 °C (EtOH), lit.38 198-
201 °C.  1H NMR (300 MHz, DMSO-d6): δ 3.63-3.67 (4H, m, CH2OCH2), 
3.79 (4H, br s, CH2NCH2), 6.99 (2H, br s, NH2), 7.54 (2H, d, J = 8.7 Hz, H-3′ 
and H-5′), 8.30 (2H, d, J = 8.7 Hz, H-2′ and H-6′). 13C NMR (75 MHz, 
DMSO-d6): δ 43.1 (CH2NCH2), 65.9 (CH2OCH2), 128.2 (2C), 129.5 (2C), 
135.7, 136.0, 164.8 (C-6), 167.1 (C-2), 168.7 (C-4). Anal. Calcd for 
C13H14ClN5O: C, 53.52; H, 4.84; N, 24.01. Found: C, 53.39; H, 4.97; N, 
23.94.  
4-(3-Methylphenyl)-6-morpholino-1,3,5-triazin-2-amine (1e).  
White solid; yield 216 mg (32%); mp 151-152 °C (EtOH). 1H NMR (300 
MHz, DMSO-d6): δ 2.39 (3H, s, Me), 3.64-3.69 (4H, m, CH2OCH2), 3.82 (4H, 
br s, CH2NCH2), 6.97 (2H, br s, NH2), 7.32-7.40 (2H, m, H-4′ and H-5′), 
8.10-8.17 (2H, m, H-2′ and H-6′). 13C NMR (75 MHz, DMSO-d6): δ 21.0 
(Me), 43.1 (CH2NCH2), 66.0 (CH2OCH2), 125.0, 128.0, 128.2, 131.8, 136.8, 
137.2, 164.9 (C-6), 167.1 (C-2), 169.7 (C-4). Anal. Calcd for C14H17N5O: C, 
61.98; H, 6.32; N, 25.81. Found: C, 61.85; H, 6.45; N, 25.69. 
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White solid; yield 324 mg (48%); mp 167-168 °C (EtOH), lit.25 167 °C.  1H 
NMR (300 MHz, DMSO-d6): δ 2.37 (3H, s, Me), 3.63-3.67 (4H, m, 
CH2OCH2), 3.79 (4H, br s, CH2NCH2), 6.92 (2H, br s, NH2), 7.27 (2H, d, J = 
8.0 Hz, H-3′ and H-5′), 8.20 (2H, d, J = 8.2 Hz, H-2′ and H-6′). 13C NMR (75 
MHz, DMSO-d6): δ 21.0 (Me), 43.1 (CH2NCH2), 65.9 (CH2OCH2), 127.8 
(2C), 128.7 (2C), 134.1, 141.0, 164.9 (C-6), 167.1 (C-2), 169.6 (C-4). Anal. 
Calcd for C14H17N5O: C, 61.98; H, 6.32; N, 25.81. Found: C, 61.88; H, 6.41; 
N, 25.73. 
4-(4-(tert-Butyl)phenyl)-6-morpholino-1,3,5-triazin-2-amine (1g).   
White solid; yield 418 mg (53%); mp 178-179 °C (EtOH). 1H NMR (300 
MHz, DMSO-d6): δ 1.31 (9H, s, C(Me)3), 3.63-3.67 (4H, m, CH2OCH2), 3.78 
(4H, br s, CH2NCH2), 6.91 (2H, br s, NH2), 7.48 (2H, d, J = 8.6 Hz, H-3′ and 
H-5′), 8.21 (2H, d, J = 8.6 Hz, H-2′ and H-6′). 13C NMR (75 MHz, DMSO-d6): 
δ 30.9 (C(Me)3), 34.5 (C(Me)3), 43.0 (CH2NCH2), 65.9 (CH2OCH2), 124.8 
(2C), 127.6 (2C), 134.1, 153.9, 164.8 (C-6), 167.1 (C-2), 169.6 (C-4). Anal. 
Calcd for C17H23N5O: C, 65.15; H, 7.40; N, 22.35. Found: C, 65.02; H, 7.53; 
N, 22.23. 
4-(4-(N,N-Dimethylamino)phenyl)-6-morpholino-1,3,5-triazin-2-amine 
(1h).   
Yellow solid; yield 132 mg (18%); mp 209-210 °C (EtOH). 1H NMR (300 
MHz, DMSO-d6): δ 2.99 (Me), 3.62-3.65 (4H, m, CH2OCH2), 3.76 (4H, br s, 
CH2NCH2), 6.71 (2H, br s, NH2), 6.72 (2H, d, J =9.1 Hz, H-3′ and H-5′), 8.14 
(2H, d, J = 9.0 Hz, H-2′ and H-6′). 13C NMR (75 MHz, DMSO-d6): δ 39.6 
(N(Me)2), 43.0 (CH2NCH2), 65.9 (CH2OCH2), 110.8 (2C), 123.6, 129.1 (2C), 
152.3, 164.8 (C-6), 166.9 (C-2), 169.6 (C-4). Anal. Calcd for C15H20N6O: C, 
59.98; H, 6.71; N, 27.98. Found: C, 59.87; H, 6.82; N, 27.85. 
4-(4-Methoxyphenyl)-6-morpholino-1,3,5-triazin-2-amine (1i).   
Yellowish solid; yield 325 mg (45%); mp 182-183 °C (EtOH), lit.38 177-
179 °C.  1H NMR (300 MHz, DMSO-d6): δ 3.64-3.68 (4H, m, CH2OCH2), 
3.80 (4H, br s, CH2NCH2), 3.83 (3H, s, OMe), 6.88 (2H, br s, NH2), 7.02 (2H, 
d, J = 9.0 Hz, H-3′ and H-5′), 8.28 (2H, d, J = 9.0 Hz, H-2′ and H-6′). 13C 
NMR (75 MHz, DMSO-d6): δ 43.1 (CH2NCH2), 55.2 (OMe), 66.0 
(CH2OCH2), 113.4 (2C), 129.2, 129.5 (2C), 161.8, 164.9 (C-6), 167.1 (C-2), 
169.3 (C-4). Anal. Calcd for C14H17N5O2: C, 58.52; H, 5.96; N, 24.38. 
Found: C, 58.39; H, 6.08; N, 24.23. 
4-(4-(Trifluoromethoxy)phenyl)-6-morpholino-1,3,5-triazin-2-amine (1j).  
White solid; yield 220 mg (26%); mp 141-142 °C (EtOH). 1H NMR (300 
MHz, DMSO-d6): δ 3.64-3.67 (4H, m, CH2OCH2), 3.79 (4H, br s, CH2NCH2), 
7.04 (2H, br s, NH2), 7.46 (2H, d, J = 8.9 Hz, H-3′ and H-5′), 8.40 (2H, d, J = 
8.9 Hz, H-2′ and H-6′). 13C NMR (75 MHz, DMSO-d6): δ 43.1 (CH2NCH2), 
65.9 (CH2OCH2), 119.9 (q, J = 257.4 Hz, OCF3), 120.4 (2C), 129.8 (2C), 
136.0, 150.4 (q, J = 1.5 Hz), 164.8 (C-6), 167.1 (C-2), 168.5 (C-4). Anal. 
Calcd for C14H14F3N5O2: C, 49.27; H, 4.13; N, 20.52. Found: C, 49.13; H, 
4.29; N, 20.40. 
6-Morpholino-4-(3-phenoxyphenyl)-1,3,5-triazin-2-amine (1k).  
White solid; yield 480 mg (55%); mp 147-148 °C (EtOH). 1H NMR (300 
MHz, DMSO-d6): δ 3.62-3.65 (4H, m, CH2OCH2), 3.76 (4H, br s, CH2NCH2), 
6.95 (2H, br s, NH2), 7.04 (2H, m, H-6″ and H-2″), 7.13-7.22 (2H, m, H-4′ 
and H-4″), 7.37-7.45 (2H, m, H-3″ and H-5″), 7.49 (1H, t, J = 7.9 Hz, H-5′), 
7.90 (1H, dd, J = 1.4, 2.5 Hz, H-2′), 8.09 (1H, ddd, J = 1.2, 1.4, 7.8 Hz, H-6′). 
13C NMR (75 MHz, DMSO-d6): δ 43.1 (CH2NCH2), 65.9 (CH2OCH2), 117.7 
(C-2′), 118.4 (2C), 121.6, 122.9, 123.4, 129.8, 130.0 (2C), 139.0, 156.5, 
156.7, 164.8 (C-6), 167.1 (C-2), 169.0 (C-4). Anal. Calcd for C19H19N5O2: C, 
65.32; H, 5.48; N, 20.04. Found: C, 65.19; H, 5.63; N, 19.88. 
4-(3-(Benzyloxy)phenyl)-6-morpholino-1,3,5-triazin-2-amine (1l).   
Light brown solid; yield 362 mg (40%); mp 161-162 °C (MeCN). 1H NMR 
(300 MHz, DMSO-d6): δ 3.60-3.69 (4H, m, CH2OCH2), 3.78 (4H, br s, 
CH2NCH2), 5.17 (2H, s, OCH2Ph), 6.97 (2H, br s, NH2), 7.18 (1H, ddd, J = 
1.0, 2.6, 8.2 Hz, H-4′), 7.30-7.44 (4H, m, H-5′, H-3″, H-4″ and H-5″), 7.46-
7.51 (2H, m, H-2″ and H-6″), 7.88-7.96 (2H, m, H-2′ and H-6′). 13C NMR 
(75 MHz, DMSO-d6): δ 43.1 (CH2NCH2), 65.9 (CH2OCH2), 69.2 (OCH2Ph), 
113.9, 117.7, 120.3, 127.6 (2C), 127.8, 128.4 (2C), 129.2, 137.0, 138.4, 
158.2, 164.8 (C-6), 167.1 (C-2), 169.4 (C-4). Anal. Calcd for C20H21N5O2: C, 
66.10; H, 5.82; N, 19.27. Found: C, 65.89; H, 5.96; N, 19.11. 
4-(4-(Benzyloxy)phenyl)-6-morpholino-1,3,5-triazin-2-amine (1m).   
Yellow solid; yield 641 mg (71%); mp 164-165 °C (EtOH). 1H NMR (300 
MHz, DMSO-d6): δ 3.61-3.66 (4H, m, CH2OCH2), 3.78 (4H, br s, CH2NCH2), 
5.17 (2H, s, OCH2Ph), 6.86 (2H, br s, NH2), 7.09 (2H, d, J = 9.0 Hz, H-3′ and 
H-5′), 7.31-7.51 (5H, m, OCH2Ph), 8.25 (2H, d, J = 8.9 Hz, H-2′ and H-6′). 
13C NMR (75 MHz, DMSO-d6): δ 43.1 (CH2NCH2), 65.9 (CH2OCH2), 69.3 
(OCH2Ph), 114.2 (2C), 127.7 (2C), 127.8, 128.4 (2C), 129.3, 129.5 (2C), 
136.7, 160.9, 164.8 (C-6), 167.0 (C-2), 169.2 (C-4). Anal. Calcd for 
C20H21N5O2: C, 66.10; H, 5.82; N, 19.27. Found: C, 65.98; H, 5.90; N, 19.13. 
4-(3,4-Dimethoxyphenyl)-6-morpholino-1,3,5-triazin-2-amine (1n).   
White solid; yield 297 mg (37%); mp 172-173 °C (EtOH).  1H NMR (300 
MHz, DMSO-d6): δ 3.63-3.67 (4H, m, CH2OCH2), 3.78 (4H, br s, CH2NCH2), 
3.81 (3H, s, OMe), 3.82 (3H, s, OMe), 6.87 (2H, br s, NH2), 7.03 (1H, d, J = 
8.6 Hz, H-5′), 7.85 (1H, d, J = 2.0 Hz, H-2′), 7.93 (1H, dd, J = 2.0, 8.5 Hz, H-
6′). 13C NMR (75 MHz, DMSO-d6): δ 43.1 (CH2NCH2), 55.3 (OMe), 55.4 
(OMe), 65.9 (CH2OCH2), 110.7, 110.9, 121.3, 129.2, 148.1, 151.5, 164.8 
(C-6), 167.0 (C-2), 169.3 (C-4). Anal. Calcd for C15H19N5O3: C, 56.77; H, 
6.03; N, 22.07. Found: C, 56.69; H, 6.10; N, 21.98.  
4-(3,4,5-Trimethoxyphenyl)-6-morpholino-1,3,5-triazin-2-amine (1o).   
White solid; yield 358 mg (41%); mp 234-235 °C (EtOH), lit.39 240 °C.  1H 
NMR (300 MHz, DMSO-d6): δ 3.64-3.67 (4H, m, CH2OCH2), 3.73 (3H, s, 
OMe), 3.77 (4H, br s, CH2NCH2), 3.84 (6H, s, 2 x OMe), 6.94 (2H, br s, NH2), 
7.62 (2H, s, H-2′ and H-6′). 13C NMR (75 MHz, DMSO-d6): δ 43.1 
(CH2NCH2), 55.8 (2 x OMe), 60.0 (OMe), 65.9 (CH2OCH2), 105.0 (2C), 
132.2, 140.3, 152.5 (2C), 164.8 (C-6), 167.0 (C-2), 169.2 (C-4). Anal. Calcd 
for C16H21N5O4: C, 55.32; H, 6.09; N, 20.16. Found: C, 55.23; H, 6.22; N, 
19.99.  
6-Morpholino-4-(thiophen-2-yl)-1,3,5-triazin-2-amine (1p).   
Light brown solid; yield 352 mg (53%); mp 145-146 °C (EtOH). 1H NMR 
(300 MHz, DMSO-d6): δ 3.62-3.66 (4H, m, CH2OCH2), 3.75 (4H, br s, 
CH2NCH2), 6.96 (2H, br s, NH2), 7.16 (1H, dd, J = 3.7, 5.0 Hz, H-4′), 7.73 
(1H, dd, J = 1.3, 5.0 Hz, H-5′), 7.88 (1H, dd, J = 1.2, 3.7 Hz, H-3′). 13C NMR 
(75 MHz, DMSO-d6): δ 43.0 (CH2NCH2), 65.9 (CH2OCH2), 127.9, 129.1, 
130.6, 142.7, 164.4 (C-6), 166.1 (C-2), 166.8 (C-4). Anal. Calcd for 
C11H13N5OS: C, 50.18; H, 4.98; N, 26.60. Found: C, 50.06; H, 5.07; N, 26.39.  
6-Phenyl-4-pyrrolidino-1,3,5-triazin-2-amine (1q).   
White solid; yield 87 mg (14%); mp 230-231 °C (EtOH), lit.24 230 °C. 1H 
NMR (300 MHz, DMSO-d6): δ 1.88-1.94 (4H, m, CH2CH2), 3.44-3.50 (2H, 
m, CH2NCH2), 3.58-3.64 (2H, m, CH2NCH2), 6.82 (2H, br s, NH2), 7.42-7.54 
(3H, m, H-3′, H-4′, and H-5′), 8.27-8.32 (2H, m, H-2′ and H-6′). 13C NMR 
(75 MHz, DMSO-d6): δ 24.65 (CH2), 24.73 (CH2), 45.6 (CH2N), 45.8 
(CH2N), 127.6 (2C), 128.0 (2C), 130.9, 137.1, 163.5 (C-6), 166.9 (C-2), 
169.1 (C-4). Anal. Calcd for C13H15N5: C, 64.71; H, 6.27; N, 29.02. Found: 
C, 64.55; H, 6.47; N, 28.90.  
6-Phenyl-4-piperidino-1,3,5-triazin-2-amine (1r).   
White solid; yield 61 mg (10%); mp 146-147 °C (EtOH), lit.40 149-151 °C. 
1H NMR (300 MHz, DMSO-d6): δ 1.46-1.55 (4H, m, CH2CH2CH2), 1.59-1.66 
(4H, m, CH2CH2CH2), 3.80 (4H, br s, CH2NCH2), 6.84 (2H, br s, NH2), 7.42-
7.53 (3H, m, H-3′, H-4′, and H-5′), 8.26-8.31 (2H, m, H-2′ and H-6′). 13C 
NMR (75 MHz, DMSO-d6): δ 24.2 (CH2), 25.3 (2 x CH2), 43.4 (CH2NCH2), 
127.6 (2C), 128.0 (2C), 131.0, 137.1, 164.5 (C-6), 167.2 (C-2), 169.5 (C-
4). Anal. Calcd for C14H17N5: C, 65.86; H, 6.71; N, 27.43. Found: C, 65.73; 
H, 6.85; N, 27.28. 
4-(4-Methylpiperidino)-6-phenyl-1,3,5-triazin-2-amine (1s).   
White solid; yield 58 mg (9%); mp >300°C (EtOH).  1H NMR (300 MHz, 
DMSO-d6): δ 0.93 (3H, d, J = 6.3 Hz, Me), 1.00-1.11 (2H, m, CH2CHMeCH2-
ax), 1.61-1.71 (3H, m, CHMe, CH2NCH2-ax), 2.86 (2H, br t, J = 12.2 Hz, 
CH2CHMeCH2-eq), 4.72 (1H, br s, NCH2-eq), 4.81 (1H, br s, NCH2-eq), 6.85 
(2H, br s, NH2), 7.42-7.53 (3H, m, H-3′, H-4′, and H-5′), 8.26-8.31 (2H, m, 
H-2′ and H-6′). 13C NMR (75 MHz, DMSO-d6): δ 21.7 (Me), 30.6 (2 x CH2), 
33.5 (CHMe), 42.7 (CH2NCH2), 127.6 (2C), 128.0 (2C), 131.0, 137.1, 164.5 
(C-6), 167.2 (C-2), 169.6 (C-4).  Anal. Calcd for C15H19N5: C, 66.89; H, 7.11; 
N, 26.00. Found: C, 66.78; H, 7.23; N, 25.83. 
4-(4-Methylpiperazino)-6-phenyl-1,3,5-triazin-2-amine (1t).  
Yield 231 mg (34%); mp 173-174 °C (EtOH), lit.22 171-174 °C.  1H NMR 
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CH2N(Me)CH2), 3.81 (4H, br s, CH2NCH2), 6.92 (2H, br s, NH2), 7.42-7.55 
(3H, m, H-3′, H-4′, and H-5′), 8.26-8.31 (2H, m, H-2′ and H-6′). 13C NMR 
(75 MHz, DMSO-d6): δ 42.4 (NMe), 45.7 (CH2NCH2), 54.3 (CH2N(Me)CH2), 
127.7 (2C), 128.1 (2C), 131.1, 136.9, 164.7 (C-6), 167.1 (C-2), 169.6 (C-
4).  Anal. Calcd for C14H18N6: C, 62.20; H, 6.71; N, 31.09. Found: C, 62.07; 
H, 6.82; N, 30.92. 
4-(3,4-Dihydroisoquinolin-2(1H)-yl)-6-phenyl-1,3,5-triazin-2-amine (1u).   
Yellowish solid; yield 290 mg (38%); mp 139-140 °C (EtOH).  1H NMR 
(300 MHz, DMSO-d6): δ 2.88 (2H, br t, J = 6.0 Hz, NCH2CH2), 4.01 (1H, br s, 
NCH2CH2), 4.11 (1H, br s, NCH2CH2), 4.89 (1H, br s, NCH2Ar), 5.02 (1H, br 
s, NCH2Ar), 6.96 (2H, br s, NH2), 7.18-7.32 (4H, m, NCH2ArCH2), 7.45-7.58 
(3H, m, H-3′, H-4′, and H-5′), 8.32-8.37 (2H, m, H-2′ and H-6′). 13C NMR 
(75 MHz, DMSO-d6): δ 28.4 (NCH2CH2), 40.4 (NCH2CH2), 44.9 (NCH2Ar), 
126.0, 126.2, 126.3, 127.7 (2C), 128.1 (2C), 131.1, 133.7 (br s), 134.7, 
136.9, 164.8 (C-6), 167.1 (C-2), 169.6 (C-4).  Anal. Calcd for C18H17N5: C, 
71.27; H, 5.65; N, 23.09. Found: C, 71.17; H, 5.76; N, 22.91. 
X-ray crystal structure determination 
Intensity data for 1l and 1n were measured for colourless crystals (11: 
0.07 × 0.17 × 0.19 mm; 1m: 0.10 × 0.15 × 0.18 mm) at 100 K on an 
Rigaku/Oxford Diffraction XtaLAB Synergy diffractometer (Dualflex, 
AtlasS2) fitted with CuK radiation ( = 1.54178 Å) so that θ(100% data 
completeness) = 67.1 and 67.7°, respectively.  Data reduction and 
Gaussian absorption corrections were by standard methods.41 The 
structures were solved by direct methods42 and refined (anisotropic 
displacement parameters and with C-bound H atoms included in the 
riding model approximation) on F2.43  The N-bound H atoms were 
refined with N–H = 0.88 ± 0.01 Å.  A weighting scheme of the form w = 
1/[σ2(Fo2) + (aP)2 + bP], where P = (Fo2 + 2Fc2)/3), was introduced in 
each case.  The molecular structure diagrams showing 70% probability 
displacement ellipsoids were generated by ORTEP for Windows44 and 
the packing diagrams with DIAMOND.45  Additional data analysis was 
made with PLATON.46 
Crystal data for 1l. C20H21N5O2, M = 363.42, triclinic, P¯1, a = 5.32441(9), 
b = 9.52388(12), c = 17.7526(3) Å, α = 90.2806(12), β = 97.7765(14), γ = 
91.0148(12)°, V = 891.77(2) Å3, Z = 2, Dx = 1.353 g cm-3, F(000) = 384, μ = 
0.737 mm-1, no. reflns meas. = 21209, no. unique reflns = 3185 (Rint = 
0.020), no. reflns with I ≥ 2σ(I) = 3083, no. parameters = 250, R(obs. 
data) = 0.033, a and b in weighting scheme = 0.051 and 0.256, wR2(all 
data) = 0.090. CCDC deposition number: 2035574. 
Crystal data for 1n. C15H19N5O3, M = 317.35, monoclinic, P21/c, a = 
8.2512(2), b = 14.9301(4), c = 12.1258(3) Å, β = 99.743(3)°, V = 
1472.25(7) Å3, Z = 4, Dx = 1.432 g cm-3, F(000) = 672, μ = 0.853 mm-1, no. 
reflns meas. = 19752, no. unique reflns = 3045 (Rint = 0.042), no. reflns 
with I ≥ 2σ(I) = 2746, no. parameters = 216, R(obs. data) = 0.042, a and b 
in weighting scheme = 0.078 and 0.443, wR2(all data) = 0.126. CCDC 
deposition number: 2035575. 
Antiproliferative activity screening  
The Jurkat-T cells (human leukemic T cell, clone E6-1) from American 
Type Culture Collection (ATCC) were cultured in RPM1-1640 medium 
(Nacalai Tesque, Japan) supplemented with 10% v/v foetal bovine serum 
(FBS) (Biosera, France) and maintained at 37 °C in a humidified 5% CO2 
incubator (Thermo Fisher, USA).  The MTS assay47 was used in the cell 
viability experiments. A total of 2 × 104 cells in 50 µL cell culture media 
were seeded into each well of a 96-well plate and incubated for 24 h.  
Then, tested compounds or reference drugs [6-mercaptopurine (Merck 
Millipore, Germany), methotrexate (Merck Millipore, Germany), and 
cytarabine (Merck Millipore, Germany)] were added followed by the 
incubation for 72 h.  After that, a mixture of 3-(4,5-dimethylthiazol-2-yl)-
5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium inner 
salt (MTS) (Sigma Aldrich, USA) and phenazine methosulfate (Nacalai 
Tesque, Japan) was added to each well, followed by another incubation 
for 1-4 h at 37 ºC.  The absorbance in each well was measured at 490 nm 
using a microplate reader (Tecan NanoQuant Infinite M200 Pro, Austria).  
The percentage of cell viability was estimated by comparing absorbance 
in wells with the treated and untreated (vehicle control) cells using the 
following formula: ODtreated/ODuntreated x 100%. All experiments were 
done in triplicates and repeated in three independent experiments.  The 
GI50 values were calculated using sigmoidal concentration-response 
curves generated by the GraphPad Prism 8 program.48 
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Table S1. Optimization of reaction conditions for the synthesis of  
4-(4-methylphenyl)-6-morpholino-1,3,5-triazin-2-amine (1f) under 
microwave irradiation 




Figure S2. Molecular packing in 1n. .………………… 5 
Copies of 1H and 13C NMR spectra for prepared 4-aryl-6-cycloamino-
1,3,5-triazin-2-amines (1a-u) 
Figure S3. Concentration-dependent antiproliferative effect of 1u 












































































Table S1. Optimization of reaction conditions for the synthesis of 4-(4-methylphenyl)-6-
morpholino-1,3,5-triazin-2-amine (1f) under microwave irradiation.a  
 
Entry Solvent Temperature, °C Reaction time, min Yield,b % 
(i) (ii) 
1 MeOH 140 20 15 33 
2 EtOH 140 20 15 37 
3 PrOH 140 20 15 9 
4 EtOH 130 20 15 28 
5 EtOH 150 20 15 31 
6 EtOH 140 15 15 20 
7 EtOH 140 30 15 38 
8 EtOH 140 40 15 40 
9 EtOH 140 50 15 39 
10 EtOH 140 55 15 44 
11 EtOH 140 60 15 39 
12 EtOH 140 55 5 39 
13 EtOH 140 55 10 43 
14 EtOH 140 55 20 48 
15 EtOH 140 55 25 46 
16 EtOH 140 55 60 41 
17c EtOH 140 55 20 33 
18d EtOH 140 55 20 26 
19e EtOH 140 55 20 6 
20f EtOH 140 55 20 33 
a The reactions were performed in a Monowave 400 microwave reactor (Anton Paar, Austria) 
using cyanoguanidine (2.5 mmol), p-tolualdehyde (2.5 mmol), morpholine (2.5 mmol), and conc. 
HCl (2.5 mmol) in 2 mL of the specified solvent in step (i) and addition of 1 mL of 5 N NaOH 
(aq.) in step (ii).  
b Isolated yield calculated on the basis of cyanoguanidine.  
c The reaction was carried out using 5 mmol of p-tolualdehyde.  
d Another 2.5 mmol of p-tolualdehyde was added to the reaction mixture in step (ii).  
e 0.5 mL of 5 N NaOH (aq.) [2.5 mmol] was used in step (ii).  
f The reaction was performed in a Monowave 50 reactor (Anton Paar, Austria) without 






































































Figure S1. Molecular packing in 1l: a view in projection down the a-axis of the unit cell 
contents.  The N‒H…O, N‒H…N, and π…π interactions are shown as orange, blue, and purple 
dashed lines, respectively. 
 
Geometric parameters (Å, °) characterising the identified intermolecular interactions: 
A H B A‒H H…B A…B A‒H…B symmetry 
       operation 
N2 H1n N3 0.893(9) 2.129(9) 3.0160(12) 172.2(10) 1-x, 2-y, 1-z 
N2 H2n O1 0.879(11) 2.138(12) 2.9903(11) 163.4(10) 1+x, 1+y, z 
Cg(N1-N3,C2,C4,C6) 






































































Figure S2. Molecular packing in 1n: a view in projection down the a-axis of the unit cell 
contents.  The N‒H…O, N‒H…N, C‒H…O, and π…π interactions are shown as orange, blue, 
green, and purple dashed lines, respectively.  One supramolecular layer is highlighted in space-
filling mode. 
 
Geometric parameters (Å, °) characterising the identified intermolecular interactions: 
A H B A‒H H…B A…B A‒H…B symmetry 
       operation 
N2 H1n O3 0.877(13) 2.108(12) 2.9634(14) 165.0(15) -1+x, ½-y, -½+z 
N2 H2n N5 0.880(15) 2.381(15) 3.2417(16) 165.8(13) x, ½-y, -½+z 
C62 H62a O1 0.99 2.39 3.3434(16) 161 1+x, ½-y, -½+z 
C47 H47b O1 0.98 2.53 3.3496(16) 141 -x, 1-y, 2-z 
Cg(N1-N3,C2,C4,C6) 
  Cg(C41-C46)  3.8765(7) 11.28(6) -x, 1-y, 1-z 
Cg(N1-N3,C2,C4,C6) 























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure S3. Concentration-dependent antiproliferative effect of 1u against Jurkat-T cells after the 
incubation for 72 h.  
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